Global Migraine Market
Tamanho do mercado em biliões de dólares
CAGR :
% 
USD
3.95 Billion
USD
5.45 Billion
2024
2032
 Período de previsão |
2025 –2032 |
 Tamanho do mercado (ano base ) | USD 3.95 Billion |
 Tamanho do mercado ( Ano de previsão) | USD 5.45 Billion |
 CAGR |
% |
| Principais participantes do mercado |
|
Global Migraine Market Segmentation, By Types (Episodic, Chronic), Symptoms (Food Cravings, Depression, Fatigue, Frequent Yawning, Hyperactivity, Irritability, Neck Stiffness, Others), Treatment (Medication, Acupressure, Counseling, Hormone Therapy, Others), Diagnosis (Computerized Tomography (CT) Scan, Magnetic Resonance Imaging (MRI), Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2032
Migraine Market Analysis
In recent years, the migraine market is anticipated to grow rapidly during the forecast period. Migraine is the world's 19th most prevalent cause of disability, according to the World Health Organization. Migraine sufferers take twice as many prescription drugs and visit doctors and emergency rooms twice as often as individuals who do not suffer from the condition. Migraine sufferers have also spent significantly more on healthcare. Migraine sufferers are observed to consume 2.5 times as many prescription drugs and have six times the number of diagnostic tests and services as non-migraine sufferers. As a result of the rising occurrence of migraine, more therapies are being used to provide relief, which serves to drive the entire market.
Migraine Market Size
Global migraine market size was valued at USD 3.95 billion in 2024 and is projected to reach USD 5.45 billion by 2032, with a CAGR of 4.10% during the forecast period of 2025 to 2032.
Report Scope and Market Segmentation
|
Attributes |
Migraine Key Market Insights |
|
Segmentation |
|
|
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Key Market Players |
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.(Jerusalem), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Bayer AG (Germany), Eli Lilly and Company (US), Merck & Co., Inc. (US), Allergan (Ireland), AstraZeneca (UK), Johnson & Johnson Private Limited (US), Cipla Inc. (US), Amneal Pharmaceuticals LLC. (US), Eisai Co., Ltd. (Japan), Bausch Health Companies Inc. (Canada), Abbott (US), Takeda Pharmaceutical Company Limited (Japan), WOCKHARDT (Mumbai), AbbVie Inc. (US), Merck KGaA (Germany) |
|
Market Opportunities |
|
Migraine Market Definition
Migraine is a neurological illness that causes throbbing pain in the forehead, side of the head, or around the eyes in one person only. Autonomic symptoms such as nausea, vomiting, photophobia, and phonophobia are frequently associated with the pain. Migraine is usually diagnosed by looking at the patient's medical history and symptoms, as well as performing blood tests and MRI and CT scans. To ease the symptoms and lessen the frequency and intensity of migraine attacks, over-the-counter (OTC) medications and prescription injections are currently available. These medications are taken either on a regular basis or in response to attacks or exacerbations of chronic pain.
Migraine Market Dynamics
Drivers
- Increasing Prevalence of Migraine
The rising prevalence of migraine is a primary driver of the migraine market's growth. Growing addiction of smoking and increasing alcohol consumption are the major factors that will enhance the prevalence of migraine and influencing the market dynamics during the forecast period.
- Rising Demand for Precision Medicines
Growing demand for precision medicines will enhance the growth rate of market. Along with this, the improvement in reimbursement policies for migraine medications will propel the market’s growth rate.
- Increasing Investment for Healthcare Infrastructure
Another significant factor influencing the growth rate of migraine market is the rising healthcare expenditure which helps in improving its infrastructure.
Furthermore, rising initiatives by public and private organizations to spread awareness will expand the migraine market. Additionally, high disposable income and increasing demand for nerve stimulation devices to treat migraine will result in the expansion of migraine market. Along with this, rising geriatric population and the advent of calcitonin gene-related peptide (CGRP) monoclonal antibodies will enhance the growth rate of the market.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the migraine market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.
Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the migraine market growth during the forecast period.
Restraints/Challenges
On the other hand, the high cost associated with the treatment of migraine will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the migraine market. Additionally, a decline in clinical visits due to COVID0-19 outbreak and procedural treatment of migraines due to social distancing norms will act as restrain and further impede the growth rate of market during the forecast period of 2025-2032.
This migraine market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the migraine market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Migraine Market Scope
The migraine market is segmented on the basis of type, symptoms, treatment, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Types
- Episodic
- Chronic
Symptoms
- Food Cravings
- Depression
- Fatigue
- Frequent Yawning
- Hyperactivity
- Irritability
- Neck Stiffness
- Others
Treatment
- Medication
- Acupressure
- Counseling
- Hormone Therapy
- Others
Diagnosis
- Computerized Tomography (CT) Scan
- Magnetic Resonance Imaging (MRI)
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Migraine Market Regional Analysis
The Migraine market is analyzed and market size insights and trends are provided by country, treatment, diagnosis, route of administration, end-users and distribution channel as referenced above.
The countries covered in the Migraine market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the migraine market because of the growing prevalence of migraine in this region. Additionally, growing focus of major key players on novel technology will further propel the market’s growth rate in this region.
Asia-Pacific are expected to grow during the forecast period of 2025 to 2032 due to rise in the number of population and rising healthcare expenditure in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Migraine Market Share
The Migraine market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to migraine market.
Migraine Market Leaders Operating in the Market Are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (US)
- Teva Pharmaceutical Industries Ltd.(Jerusalem)
- Sanofi (France)
- Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Eli Lilly and Company (US)
- Merck & Co., Inc. (US)
- Allergan (Ireland)
- AstraZeneca (UK)
- AbbVie Inc. (US)
- WOCKHARDT (Mumbai)
- Johnson & Johnson Private Limited (US)
- Cipla Inc. (US)
- Amneal Pharmaceuticals LLC. (US)
- Eisai Co., Ltd. (Japan)
- Bausch Health Companies Inc. (Canada)
- Abbott (US)
- Takeda Pharmaceutical Company Limited (Japan)
- Merck KGaA (Germany)
Latest Developments in Migraine Market
- In September 2021, FDA had approved the first and only oral CGRP receptor antagonist named QULIPTA™ (atogepant), which is specifically developed for the preventive treatment of migraine. CGRP and its receptors are used for nervous system associated with migraine pathogenesis, and CGRP levels have been found to be higher during migraine attacks in studies. QULIPTA is a once-daily medication that blocks CGRP. It comes in three different strengths including 10 mg, 30 mg, and 60 mg
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
